* patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to tocilizumab or to any of their excipients. * pregnancy * current documented bacterial infection * patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

* patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to tocilizumab or to any of their excipients. * pregnancy * current documented bacterial infection * patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

- patients with exclusion criteria to the corimuno-19 cohort. - known hypersensitivity to tocilizumab or to any of their excipients. - pregnancy - current documented bacterial infection - patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n

- patients with exclusion criteria to the corimuno-19 cohort. - known hypersensitivity to tocilizumab or to any of their excipients. - pregnancy - current documented bacterial infection - patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n